ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

[1]  Maximilian Burger,et al.  Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. , 2012, The Journal of urology.

[2]  M. Soloway,et al.  The importance of transurethral resection in managing patients with urothelial cancer in the bladder: proposal for a transurethral resection of bladder tumor checklist. , 2012, European urology.

[3]  R. Meijer,et al.  A plea for long-term surveillance in bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer. , 2012, European urology.

[4]  T. Wilt,et al.  Intravesical gemcitabine therapy for non‐muscle invasive bladder cancer (NMIBC): a systematic review , 2012, BJU international.

[5]  A. Bossi.  Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 2011;59:1009-18. , 2011, European urology.

[6]  H. Grossman,et al.  Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. , 2011, European urology.

[7]  J. Witjes,et al.  Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. , 2011, European urology.

[8]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.

[9]  J. Witjes,et al.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. , 2011, European urology.

[10]  S. Albisinni,et al.  Long-term experience with early single Mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial , 2011, World Journal of Urology.

[11]  H. Herr,et al.  Reduced bladder tumour recurrence rate associated with narrow‐band imaging surveillance cystoscopy , 2011, BJU international.

[12]  M. Soloway,et al.  Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done? , 2010, Urology.

[13]  A. Bohle.  Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd , 2010 .

[14]  Y. Lotan,et al.  Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. , 2010, The Journal of urology.

[15]  T. D. de Reijke,et al.  Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd , 2010, European urology.

[16]  R. Autorino,et al.  Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer , 2010, Cancer.

[17]  M. Babjuk,et al.  Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. , 2010, European urology.

[18]  A. Devasia,et al.  Re: Guido Dalbagni, Kinjal Vora, Matthew Kaag, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009;56:903-10. , 2010, European urology.

[19]  Dieter Jocham,et al.  Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. , 2010, European urology.

[20]  A. Bohle.  Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study , 2010 .

[21]  Yair Lotan,et al.  Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. , 2010, European urology.

[22]  M. Soloway,et al.  "Complete transurethral resection of bladder tumor": are the guidelines being followed? , 2010, Urology.

[23]  B. Bochner,et al.  Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. , 2009, European urology.

[24]  A. Bohle.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer , 2009 .

[25]  J. Witjes,et al.  Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. , 2009, The Journal of urology.

[26]  Yair Lotan,et al.  Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. , 2009, European urology.

[27]  A. Böhle,et al.  Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. , 2009, European urology.

[28]  A. Sankila,et al.  Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. , 2009, European urology.

[29]  J. Wright,et al.  Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis. , 2008, The Journal of urology.

[30]  M. O'Donnell,et al.  Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. , 2008, Urology.

[31]  M. Soloway.  It is time to abandon the "superficial" in bladder cancer. , 2007, European urology.

[32]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[33]  J. Witjes,et al.  High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. , 2005, Urology.

[34]  H. Herr.  Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. , 2005, The Journal of urology.

[35]  Antonio Alcaraz,et al.  Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. , 2005, The Journal of urology.

[36]  J. Witjes,et al.  Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. , 2005, The Journal of urology.

[37]  M. Soloway.  Re: Schrier BPh, Hollander MP, van Rhijn BWG, Kiemeney LALM, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004;45:292-6. , 2005, European urology.

[38]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[39]  R. Sylvester,et al.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. , 2004, The Journal of urology.

[40]  T. Wilt,et al.  Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials , 2004, BJU international.

[41]  L. Kiemeney,et al.  Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. , 2004, European urology.

[42]  G. Dalbagni,et al.  Defining bacillus Calmette-Guerin refractory superficial bladder tumors. , 2003, The Journal of urology.

[43]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[44]  H. Herr.  Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder? , 2001, BJU international.

[45]  J. Chin,et al.  Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. , 2001, Journal of the National Cancer Institute.

[46]  R Sylvester,et al.  Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. E , 1995, The Journal of urology.

[47]  M. Soloway.  Rationale for intensive intravesical chemotherapy for superficial bladder cancer. , 1980, The Journal of urology.

[48]  Oxford Centre for Evidence-based Medicine Levels of Evidence (January 2001) , 2014 .

[49]  Yair Lotan,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. , 2013, European urology.

[50]  D. Grignon,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. , 2013, European urology.

[51]  P. Malmström,et al.  Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. , 2010, European urology.

[52]  W. Otto,et al.  Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? , 2008, European urology.

[53]  M. Soloway.  Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder. , 2006, Urologic oncology.

[54]  L. Mazzucchelli,et al.  A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. , 2003, The Journal of urology.

[55]  Richard L. Lindstrom,et al.  A multicenter prospective randomized trial , 1991 .